title: Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
authors.affiliation: Department of Clinical and Biological Sciences, University of Torino, Azienda Ospedaliero, Universitaria San Luigi, Orbassano, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Berruti
authors.forename: E
authors.initials: E
authors.lastname: Baudin
authors.forename: H
authors.initials: H
authors.lastname: Gelderblom
authors.forename: H R
authors.initials: HR
authors.lastname: Haak
authors.forename: F
authors.initials: F
authors.lastname: Porpiglia
authors.forename: M
authors.initials: M
authors.lastname: Fassnacht
authors.forename: G
authors.initials: G
authors.lastname: Pentheroudakis
mesh_terms: D000310:Adrenal Gland Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy; D000315:Adrenalectomy; D018268:Adrenocortical Carcinoma / Q000175:diagnosis* / Q000556:secondary / Q000628:therapy; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D059186:Chemoradiotherapy, Adjuvant; D006801:Humans; D008939:Mitotane / Q000627:therapeutic use; D009367:Neoplasm Staging; D009376:Neoplasms, Hormone-Dependent / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy; D010673:Pheochromocytoma / Q000175:diagnosis* / Q000556:secondary / Q000628:therapy; D018570:Risk Assessment
chemical_list: D018931:Antineoplastic Agents, Hormonal; D008939:Mitotane